Page 40 - Naplex Q&A 2025 Version

www.pharmacyexam.com

intraocular use. It is indicated for the treatment of should be strictly avoided. Concurrent use of
patients with neovascular (wet) age-related macular Cefotetan with Toradol (Ketorolac tromethamine)
degeneration (AMD) and macular edema following may aggravate the bleeding tendency in patients by
retinal vein occlusion (RVO). It is required to be inhibiting the aggregation of platelets. The
stored in a refrigerator. simultaneous use of Toradol with Cefotetan may
require the close supervision. Antivert (Meclizine) is
17. (a) Toradol (Ketorolac tromethamine) is an antihistamine indicated for the treatment of
classified as an NSAID. It is indicated for the short- vertigo and motion sickness. It can be safely
term management of moderate to acute pain. It has administered with Toradol.
anti-inflammatory, antipyretic and analgesic
properties. It inhibits the aggregation of platelets. It 23.(d) All other choices (K-Tab, K-Dur, Micro-K and
produces ulcers and increases the risk of G.I. Klotrix) indicate the oral solid dosage forms of
bleeding by inhibiting the synthesis of potassium which would cause irritation of the G.I.
prostaglandins. tract and aggravate patient’s current ulcer
condition. Liquid and effervescent preparations of
18. (e) Toradol (Ketorolac tromethamine) is potassium (Kaochlor) are less irritable to the G.I.
generally preferred by an oral, I.V. or I.M. route. tract and are more preferable over solid dosage
The maximum recommended daily dose of Toradol forms.
(Ketorolac) for oral administration is 40 mg/day,
and for I.V./I.M. administration, it is 120 mg/day. 24.(c) The active ingredients found in Symbicort are
For an I.V. injection, at least 30 seconds should be Budesonide and Formoterol. Budesonide is a
provided so that the drug can uniformly distribute corticosteroid and Formoterol is a long acting
in the blood. Time required for I.V. administration selective beta2-agonist. It is indicated for the long-
of Toradol must not be less than 30 seconds. term, twice-daily, maintenance treatment of
asthma in patients 12 years of age and older.
19.(b) Because of its serious and dangerous adverse
effects, Toradol should not be used for more than 5 It is NOT indicated for the relief of acute
days. bronchospasm. Symbicort should be administered
twice daily every day by the orally inhaled route
20.(e) Toradol (Ketorolac tromethamine) should only. After inhalation, the patient should rinse the
never be given by intrathecal or epidural route mouth with water without swallowing.
because of its alcohol content. Its solution contains
10% w/v of alcohol. Symbicort should be primed before using for the
first time by releasing two test sprays into the air
21. (e) Toradol (Ketorolac tromethamine) may away from the face, shaking well for 5 seconds
reversibly inhibit the aggregation of platelets. before each spray. In cases where the inhaler has
Plicamycin, Valproic acid, Cefotetan, Cefoperazone not been used for more than 7 days or when it has
and Moxalactam have been reported to inhibit the been dropped, prime the inhaler again by shaking
aggregation of platelets as well. The aggregation of well for 5 seconds before each spray and releasing
platelets increases the risk of bleeding and two test sprays into the air away from the face.
therefore the concurrent use of Toradol with
Plicamycin, Valproic acid and Moxalactam may not 25.(d) Catapres (Clonidine) is classified as an alpha-
be recommended. 2 receptor agonist. It is indicated for the treatment
of hypertension. The recommended therapeutic
22.(a) Gold-compound (Auranofin), Methotrexate dose of the drug is 0.1 mg to 0.3 mg twice daily.
and Probenecid may increase the risk of
nephrotoxicity when used simultaneously with The transdermal system TTS-2 releases 0.2 mg of
Toradol (Ketorolac tromethamine). Concurrent use Clonidine per day for seven days. Catapres TTS

205